Fundraising Fox
Neurogastrx
Woburn, US · Founded 2012 · 2 employees on LinkedIn · 9 known investors
Find your way into Neurogastrx
Each arrow is one introduction. Sign up to fill in the first one.
Ask Chris Mauney to introduce you to PAUL ROGERS
You →Chris · together at Syneos Health →PAUL
Ask Jamie Chen to introduce you to Cyril De Colle
You →Jamie · together at KineMed, Inc →Cyril
Ask Sam Okafor to introduce you to JAMES O'MARA
You →Sam · together at Neurogastrx →JAMES
Sign up to find every way you can get introduced to Neurogastrx
- Your email: who you already know at Neurogastrx, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Neurogastrx team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Neurogastrx is a biopharmaceutical company developing therapies for patients with gastrointestinal disorders. It focuses on science-driven drug development to address GI conditions that affect patients' quality of life.
Founders & leadership
Neurogastrx was founded in 2012 by Cyril De Colle.
Board
Investors · 9
How we know: 5AM Ventures's portfolio page · funding news · biospace.com · Not right? Tell us
How we know: OrbiMed's portfolio page · board seat on SEC Form D · funding news · biospace.com · the VCSheet dataset · Not right? Tell us
How we know: Samsara BioCapital's portfolio page · biospace.com · Not right? Tell us
How we know: a partner's Signal profile · funding news · the VCSheet dataset · Not right? Tell us
How we know: Vivo Capital's portfolio page · biospace.com · Not right? Tell us
How we know: board seat on SEC Form D · Not right? Tell us
How we know: a partner's Signal profile · board seat on SEC Form D · Not right? Tell us
Also in the syndicate · 1
Funding
SEC filings, press & company announcements$125M disclosed across 3 rounds · 2018–2021
- $45MSeries AJan 2018 · 2 sourcesSource ↗
▶$60MraisedJul 2021 · 10 investors · BiotechnologyRule 506(b)
- AARON ROYSTONDirector
- CYRIL DE COLLEExecutive Officer, Director
- DAVID ALLISONDirector
- KLAUS VETTINGERDirector
- JAMES DETOREExecutive Officer
- PAUL ROGERSExecutive Officer
- JAMES O'MARAExecutive Officer, Director
- KEVIN KOCHDirector
- Amount sold
- $60M
- First sale
- Jun 2021
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$20MraisedJul 2021 · 4 investors · BiotechnologyRule 506(b)
- CYRIL DE COLLEExecutive Officer, Director
- JAMES DETOREExecutive Officer
- DAVID ALLISONDirector
- KLAUS VEITINGERDirector
- JAMES O'MARAExecutive Officer, Director
- KEVIN KOCHDirector
- AARON ROYSTONDirector
- PAUL ROGERSExecutive Officer
- Amount sold
- $20M
- First sale
- Jun 2021
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Neurogastrx do?
- Neurogastrx is a biopharmaceutical company developing therapies for patients with gastrointestinal disorders. It focuses on science-driven drug development to address GI conditions that affect patients' quality of life.
- Who founded Neurogastrx?
- Neurogastrx was founded by Cyril De Colle in 2012.
- Who are Neurogastrx's investors?
- Neurogastrx's investors include 5AM Ventures, OrbiMed, Samsara BioCapital, venBio Partners, Vivo Capital, RTW Investments L.P., venBio Global Strategic, Westlake Village BioPartners.
- How much funding has Neurogastrx raised?
- Neurogastrx has disclosed $125M raised across 3 rounds.
- Where is Neurogastrx headquartered?
- Neurogastrx is headquartered in Woburn, US.